Hunter Associates Investment Management LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 57,588 shares of the company’s stock after selling 1,833 shares during the period. Johnson & Johnson makes up about 2.5% of Hunter Associates Investment Management LLC’s holdings, making the stock its 6th biggest position. Hunter Associates Investment Management LLC’s holdings in Johnson & Johnson were worth $10,172,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Glassy Mountain Advisors Inc. bought a new position in shares of Johnson & Johnson in the 4th quarter worth $35,000. Retirement Financial Solutions LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $40,000. TD Capital Management LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth $48,000. VitalStone Financial LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $52,000. Finally, Iron Horse Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Stock Up 0.9 %
Shares of Johnson & Johnson stock opened at $165.18 on Wednesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The stock has a market capitalization of $430.18 billion, a PE ratio of 34.56, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $186.57. The company has a 50-day simple moving average of $157.57 and a two-hundred day simple moving average of $167.03.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.88%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 94.56%.
Insider Activity
In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on JNJ shares. Atlantic Securities cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 19th. SVB Leerink cut their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Finally, Raymond James cut their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $173.00.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- United Parcel Service Delivers A Warning To The Market
- Pulte Homes Is Hosting The Better, More Profitable Open House
- Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
- A Top Is In For McDonald’s Corporation Stock
- Strong Demand Makes Cleveland-Cliffs an Undervalued Mid-Cap
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
